Friday, April 19, 2019

Cidara has an antiviral ADC candidate

  • the company has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak:registered: influenza (antiviral) program
  • Data supporting the selection will be presented today in an oral session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Cidara is looking to combine the antiviral agent directly applied to the influenza virus while activating a patients immune system at the same time to help fight of the infection. In this was Cidara is looking to use the AVC (anti-viral conjugate) technology to provide both short-term flu infection relief, and also long-term sustained preventative relief.
The ultimate goal is to achieve influenza relief for an entire year through the application of their technology.

Initial results are being shared at the 2019 ECCMID Conference this week.

What do you think of this approach? There are a couple of companies attempting to use oncological ADC principles for non-oncology therapies. Dyne Therapeutics comes to mind. Is this the next stage of ADC development, or a niche off-shoot which is unlikely to gain major traction?

No comments:

Post a Comment